Hepatotoxicity clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.
Santa Monica, California and other locations